211 related articles for article (PubMed ID: 19075241)
1. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
Heredia A; Latinovic O; Gallo RC; Melikyan G; Reitz M; Le N; Redfield RR
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20476-81. PubMed ID: 19075241
[TBL] [Abstract][Full Text] [Related]
2. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
Latinovic O; Heredia A; Gallo RC; Reitz M; Le N; Redfield RR
Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
5. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
7. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Tsibris AM; Sagar M; Gulick RM; Su Z; Hughes M; Greaves W; Subramanian M; Flexner C; Giguel F; Leopold KE; Coakley E; Kuritzkes DR
J Virol; 2008 Aug; 82(16):8210-4. PubMed ID: 18495779
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
[TBL] [Abstract][Full Text] [Related]
9. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
[TBL] [Abstract][Full Text] [Related]
10. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
11. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
Wu E; Du Y; Gao X; Zhang J; Martin J; Mitreva M; Ratner L
J Virol; 2019 May; 93(9):. PubMed ID: 30787151
[TBL] [Abstract][Full Text] [Related]
12. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.
Heredia A; Amoroso A; Davis C; Le N; Reardon E; Dominique JK; Klingebiel E; Gallo RC; Redfield RR
Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10411-6. PubMed ID: 12915736
[TBL] [Abstract][Full Text] [Related]
15. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
Anastassopoulou CG; Ketas TJ; Sanders RW; Klasse PJ; Moore JP
Virology; 2012 Jul; 428(2):86-97. PubMed ID: 22520838
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
[TBL] [Abstract][Full Text] [Related]
17. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
18. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
[TBL] [Abstract][Full Text] [Related]
19. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
